Page 16 - Ohnson Johnson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

J&J's therapy combination of antibody treatment Rybrevant and experimental drug lazertinib showed a clinically meaningful improvement in progression-free survival rate in patients. The drugmaker expects the combination to become a first-line treatment for non small-cell lung cancer (NSCLC) patients with a type of mutation in EGFR protein that causes rapid tumor cell growth. A rival treatment combining AstraZeneca's Tagrisso and chemotherapy also recently succeeded in a late-stage study.

Medical Technology Ireland is Europe’s second largest and fastest-growing MedTech Exhibition and Conference, reflecting the dynamic medical device sector in Ireland.

The Food and Drug Administration (FDA) ruled Tuesday that a key drug in popular decongestants is ineffective, which one Canadian group of doctors has known for years.

Caesars confirms breach of its loyalty program database; MGM website and operations at many properties remain down. Casino operators Caesars Entertainment and MGM Resorts are working with law enforcement investigators as they continue to grapple with the impact of recent separate cyber attacks.The cybersecurity breaches were reported within days of each other and follow several other high-profile cyber attacks in several industries. These include hacks of a third-party database serving Johnson &

FRANKFURT (Reuters) -Novartis' generic-drugs unit Sandoz said on Monday it plans to launch a generic version of Johnson & Johnson's anti-inflammatory drug Stelara under a collaboration deal with Samsung Bioepis. For Sandoz, which is due to become an independent company early next month, the transaction means more investment in the growing market of biosimilars, which are lower-cost copies of complex biotech drugs that have lost patent protection.